6. Last week, data came out claiming that a new drug, Iecanemab, helps to slow the progression of the memory loss that happens with dementias, like Alzherimer's disease (true story!). Let's imagine that the a-level criterion that they used in their study to make this conclusion was a = .01 (two-tailed test). (4 points total) a. Are you comfortable with the researcher's claim that their drug helps to slow the progression of memory loss, given their alpha-level? Why or why not? (Hint. Think in terms of Type land Type II error.) (1 point) b. Imagine that the researcher decides to change their analysis from an initial two-tailed to a one-tailed test. What is the probability now of them rejecting the null hypothesis if the null hypothesis is "true\"? All the researcher did was change from a two- to a one-tailed test; nothing else in their study has changed. Explain your answer. (Hint. Think of whether the value of the alpha-level has changed.) (1 point) c. Imagine that the researcher decides to change their analysis from their initial two-tailed to a one-tailed test. All the researcher did was change from a two- to a one-tailed test; nothing else in their study has changed. How does this change affect the critical region of rejection? Explain your answer. (1 point) d. Imagine that the researcher decides to change their analysis from their initial two-tailed to a one-tailed test. All the researcher did was change from a two- to a one-tailed test; nothing else in their study has changed. Assuming the test-statistic is in the predicted direction, is the test-statistic more or less likely to fall into the critical region of rejection when the test is changed from a two-tailed to a one-tailed test? Explain your answer. (1 point)